- AK: We have hypothesis: people working in the vet world have shown that having a longer exposure to the drug improve the efficacy. We haven't completed the genomic analysis trying to identify if there is a difference. But the pharmacokinetic analysis shows in Phase II we couldn't identify. We only saw it in blood, not where the parasite is.
- PL: The work being done by Sanger is it full genome analysis?
- AK: sí. su approach también es ese para este proyecto.
-
- JOHN AMUASI: really a rich presentation of the clinical data. Quite a significant variation in the AE.
FMS
9 months ago